RESULTS

Over 38 million eligible health plan members representing over 88 million person-years of data for biologics, including biosimilars, is a critical public health need. The proportion of patients treated with filgrastim products has varied over time, with declining relative utilization of filgrastim and increasing utilization of filgrastim-sndz. The proportion of patients treated with a biosimilar from the reference product was observed in some patients, though the reason for switching is not available.

The proportion of patients treated with filgrastim products had varied over time, with declining relative utilization of filgrastim and increasing utilization of filgrastim-sndz. Of incident filgrastim-only users, 9.5% had a recorded history of filgrastim use and 17.1% had a history of pegfilgrastim use. Of incident filgrastim users, 1.0% had prior use of pegfilgrastim, and 0.9% prior use of pegfilgrastim-jmdb. 4.8% of current filgrastim users had a recorded history of pegfilgrastim use, and 1.3% had a recorded history of pegfilgrastim-jmdb use. This suggests some switching between products occurred. Clinical characteristics of patients evaluated during 183 days prior to the index exposure, by product, are shown in Table 3.

Figure 3. Comparison of Utilization Across All G-CSF Products by Incident Exposure

Table 2. Number of Patients withPrior Exposure to a Different G-CSF Product

Table 3. Clinical Characteristics of Patients Receiving G-CSF Treatment

CONCLUSIONS

The proportion of patients treated with a biosimilar from the reference product has varied over time, with declining relative utilization of filgrastim and increasing utilization of filgrastim-sndz. Of incident filgrastim-only users, 9.5% had a recorded history of filgrastim use and 17.1% had a history of pegfilgrastim use. Of incident filgrastim users, 1.0% had prior use of pegfilgrastim, and 0.9% prior use of pegfilgrastim-jmdb. 4.8% of current filgrastim users had a recorded history of pegfilgrastim use, and 1.3% had a recorded history of pegfilgrastim-jmdb use. This suggests some switching between products occurred. Clinical characteristics of patients evaluated during 183 days prior to the index exposure, by product, are shown in Table 3.

Figure 1. Longitudinal Utilization Trends Across Filgrastim Products by Incident Exposure

Total use of all filgrastim products remained consistent at about 6,900 users annually (Figure 1, Figure 2); however, use of filgrastim-sndz has increased from 2014 to 2017. Total use of filgrastim-sndz increased from 2014 to 2017. Total use of all filgrastim products remained consistent at about 6,900 users annually. Of incident filgrastim-only users, 9.5% had a recorded history of filgrastim use and 17.1% had a history of pegfilgrastim use. Of incident filgrastim users, 1.0% had prior use of pegfilgrastim, and 0.9% prior use of pegfilgrastim-jmdb. 4.8% of current filgrastim users had a recorded history of pegfilgrastim use, and 1.3% had a recorded history of pegfilgrastim-jmdb use. This suggests some switching between products occurred. Clinical characteristics of patients evaluated during 183 days prior to the index exposure, by product, are shown in Table 3.

Table 2. Number of Patients with Prior Exposure to a Different G-CSF Product

Table 3. Clinical Characteristics of Patients Receiving G-CSF Treatment

CONCLUSIONS

The proportion of patients treated with a biosimilar from the reference product has varied over time, with declining relative utilization of filgrastim and increasing utilization of filgrastim-sndz. Of incident filgrastim-only users, 9.5% had a recorded history of filgrastim use and 17.1% had a history of pegfilgrastim use. Of incident filgrastim users, 1.0% had prior use of pegfilgrastim, and 0.9% prior use of pegfilgrastim-jmdb. 4.8% of current filgrastim users had a recorded history of pegfilgrastim use, and 1.3% had a recorded history of pegfilgrastim-jmdb use. This suggests some switching between products occurred. Clinical characteristics of patients evaluated during 183 days prior to the index exposure, by product, are shown in Table 3.

Figure 1. Longitudinal Utilization Trends Across Filgrastim Products by Incident Exposure

Total use of all filgrastim products remained consistent at about 6,900 users annually (Figure 1, Figure 2); however, use of filgrastim-sndz has increased from 2014 to 2017. Total use of filgrastim-sndz increased from 2014 to 2017. Total use of all filgrastim products remained consistent at about 6,900 users annually. Of incident filgrastim-only users, 9.5% had a recorded history of filgrastim use and 17.1% had a history of pegfilgrastim use. Of incident filgrastim users, 1.0% had prior use of pegfilgrastim, and 0.9% prior use of pegfilgrastim-jmdb. 4.8% of current filgrastim users had a recorded history of pegfilgrastim use, and 1.3% had a recorded history of pegfilgrastim-jmdb use. This suggests some switching between products occurred. Clinical characteristics of patients evaluated during 183 days prior to the index exposure, by product, are shown in Table 3.

Figure 1. Longitudinal Utilization Trends Across Filgrastim Products by Incident Exposure

Total use of all filgrastim products remained consistent at about 6,900 users annually (Figure 1, Figure 2); however, use of filgrastim-sndz has increased from 2014 to 2017. Total use of filgrastim-sndz increased from 2014 to 2017. Total use of all filgrastim products remained consistent at about 6,900 users annually. Of incident filgrastim-only users, 9.5% had a recorded history of filgrastim use and 17.1% had a history of pegfilgrastim use. Of incident filgrastim users, 1.0% had prior use of pegfilgrastim, and 0.9% prior use of pegfilgrastim-jmdb. 4.8% of current filgrastim users had a recorded history of pegfilgrastim use, and 1.3% had a recorded history of pegfilgrastim-jmdb use. This suggests some switching between products occurred. Clinical characteristics of patients evaluated during 183 days prior to the index exposure, by product, are shown in Table 3.

Figure 1. Longitudinal Utilization Trends Across Filgrastim Products by Incident Exposure

Total use of all filgrastim products remained consistent at about 6,900 users annually (Figure 1, Figure 2); however, use of filgrastim-sndz has increased from 2014 to 2017. Total use of filgrastim-sndz increased from 2014 to 2017. Total use of all filgrastim products remained consistent at about 6,900 users annually. Of incident filgrastim-only users, 9.5% had a recorded history of filgrastim use and 17.1% had a history of pegfilgrastim use. Of incident filgrastim users, 1.0% had prior use of pegfilgrastim, and 0.9% prior use of pegfilgrastim-jmdb. 4.8% of current filgrastim users had a recorded history of pegfilgrastim use, and 1.3% had a recorded history of pegfilgrastim-jmdb use. This suggests some switching between products occurred. Clinical characteristics of patients evaluated during 183 days prior to the index exposure, by product, are shown in Table 3.